Physician profile
Renae M Meyer
NPI 1154442580
$418.89
in general payments reported to CMS, 2019-2025
11 companies · $45.46 in 2025
The $45.46 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.19 · 2020: $44.05 · 2021: $16.73 · 2022: $88.33 · 2023: $86.90 · 2024: $96.23 · 2025: $45.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $122.52 | 2021-2025 | |
| Amgen INC. | $86.73 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $58.26 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $29.02 | 2022-2024 | Airsupra |
| Allergan, INC. | $28.97 | 2020 | |
| Novartis Pharmaceuticals Corporation | $23.59 | 2024 | |
| Acadia Pharmaceuticals INC | $15.95 | 2022 | |
| Astellas Pharma US INC | $14.37 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $13.25 | 2022 | |
| Lilly USA, LLC | $13.19 | 2024 | Mounjaro |
| Pfizer INC. | $13.04 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renae Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.